Systematic Reviews
Copyright ©The Author(s) 2025.
World J Virol. Jun 25, 2025; 14(2): 106973
Published online Jun 25, 2025. doi: 10.5501/wjv.v14.i2.106973
Table 1 Context descriptions of included studies
Ref.
Study setting and population
Number of sites
Country guidelines at the time of screening
Reasons for not performing LP
Design and data sources
Quality assessment
Boyd et al[39], 2022Adults ≥ 18 years with AHD based on CD4 < 200 cells/mm3 in ZimbabweMultiple sitesART-naïve people with HIV were required to have CD4 count measurement and CrAg screening if CD4 count is ≤ 200 cells/mm3UndocumentedCross-sectional study evaluated diagnostic accuracy of point of care finger prick whole blood compared with laboratory-based serum antigen testing7
Blasich et al[40], 2021Adults ≥ 18 years with AHD based on CD4 < 100 cells/mm3 in South Africa. Identified during routine laboratory reflex screeningMultiple sites involving Helen Joseph and Tambo Memorial hospitals in South AfricaART-naïve people with HIV were required to have CD4 count measurement and CrAg screening if CD4 count is ≤ 100 cells/mm3UndocumentedProspective cohort study evaluated laboratory tests to quantify the amount of CrAg in plasma of patients with AHD and to gauge the risk of CM8
Longley et al[15], 2016ART-naive patients with no prior history of cryptococcal disease, aged > 18 years, and with a CD4 cell count ≤ 100 cells/μL in South AfricaTwo ART clinics in Cape Town, South AfricaART-naïve people with HIV were required to have CD4 count measurement and CrAg screening if CD4 count is ≤ 100 cells/mm3RefusalsProspective cohort with patients being followed for a period of one year to determine mortality among CrAg positive and negative individuals9
Enock et al[41], 2022All people living with HIV who receive routine HIV care from facilities of different administrative level in five districts (2-Urban and 3-Rural) in UgandaFourteen facilities. The fourteen health facilities (six health center level three, three health center level four, three general referral hospitals, and two regional referral hospitals)ART-naïve people with HIV were required to have CD4 count measurement and CrAg screening if CD4 count is ≤ 100 cells/mm3. Routine assessment with provider initiatedAttending rural facilities translating to training gaps and resourcesRetrospective review of medical records from CD4 and CrAg registers standard Uganda Ministry of Health (MoH) tools that are used for documentation and generation of routine performance reports9
Tiam et al[42], 2023Enrolled 15 years or older people with AHD (CD4 < 200 cells/mm3 or WHO stage III/IV)Two largest hospitals ART clinics at the Motebang and Berea District. The hospital serves one-third of Lesotho’s populationSame-day serum CrAg screening test for all patients enrolling in care with CD4 count < 200 cells/mm3. Routine assessment with provider initiatedUndocumentedProspective evaluation of routinely collected data from ART clinics. Follow up 6 months8
Blankley et al[29], 2019Enrolled 19 years or older ART naïve people with AHD (CD4 < 200 cells/mm3 or WHO stage III/IV) at a semi-urban polyclinic in Epworth, ZimbabweSingle site study at Epworth polyclinic (a nurse led with support from Me´decins Sans Frontières and Ministry of Health doctorsFrom 2015, recommended CrAg screening for those with CD4 < 100 cells/mm3. Routine assessment with provider initiatedUndocumentedRetrospective assessment of outcomes and management of patients with AHD9
Heller et al[30], 2022In patient evaluation of AHD management practices at a tertiary hospital in MalawiSingle site at Kamuzu Central Hospital. A tertiary hospital located in Lilongwe2017: Recommended CrAg screening for those with CD4 < 100 cells/mm3. 2020: Recommended CrAg screening for those with CD4 < 200 cells/mm3. Routine assessment with provider initiatedUndocumentedEvaluation of outcome for patients with AHD using routinely collected data9
Kanyama et al[31], 2022Enrolled 14 years or older in patients from a tertiary hospital. AHD diagnosis based on CD4 < 200 cells/mm3Single site at Kamuzu Central Hospital. A tertiary hospital located in LilongweBetween 1 August 2016 and 31 January 2017, CD4 cell count, urine lipoarabinomannan, urine X-pert and CrAg screening services for management of AHD were introduced. Routine assessment with provider initiatedUndocumentedProspective evaluation of routinely collected data from medical wards among patients with AHD8
Hurt et al[17], 2021Tested laboratory samples for patients with AHD based on CD4 count < 100 cells/mm3Data from 27 ART clinics and one central referral hospital in BotswanaRecommended CrAg screening for those with CD4 ≤ 100 cells/mm3. An evaluation of laboratory reflex CrAg screeningUndocumentedEvaluation of data from the Botswana. Harvard HIV reference laboratory8
Deiss et al[32], 2021People with AHD CD4 < 200 cells/mm3Enrolled from Jose Macamo General Hospital, a tertiary hospital in MozambiqueRecommended CrAg screening for those with CD4 ≤ 200 cells/mm3UndocumentedRetrospective review of routinely collected clinical data9
Braide et al[43], 2023People with AHD (CD4 < 200 cells/mm3 or WHO stage III/IV)28 healthcare facilities across 4 high-burden states in NigeriaRecommended CrAg screening for those with AHDLimited/lack of LP packsNewly identified PLHIV were screened for AHD. Those with AHD were screened for Tuberculosis and CM8
Bornstein et al[33], 2014HIV patients with CD4 < 100 cells/mm3Single site Tertiary Tikur Anbessa Hospital in Addis AbabaCrAg screening for those with CD4 ≤ 100 cells/mm3UndocumentedDiagnostic evaluation between point of care finger stick and serum lateral flow assay8
Faini et al[18], 2019Newly diagnosed PLHIV, ART-naïve adults ≥ 18 years-old, with CD4 < 150 cells/mm3Kilombero and Ulanga Antiretroviral Cohort involves patients attending Saint Francis Referral Hospital in TanzaniaCrAg screening for those with CD4 ≤ 100 cells/mm3. Routine laboratory-reflex CrAg screeningUndocumentedProspective cohort to determine mortality among CrAg positive and negative individuals9
Ndayishimiye et al[44], 2018PLHIV with CD4 < 100 cells/mm317 clinics and one hospital (Prince Mshiyeni Memorial Hospital) in South AfricaCrAg screening for those with CD4 ≤ 100 cells/mm3. Routine laboratory-reflex CrAg screeningUndocumentedRetrospective review of National Laboratory data and medical record charts7
Temfack et al[34], 2018HIV-infected, ART naïve ambulatory adults (> 18 years) CD4 < 100 cells/mm3, no history of CMDay Hospital of the Yaoundé Central Hospital in Cameroon. A tertiary hospitalCrAg screening for those with CD4 ≤ 100 cells/mm3UndocumentedProspective cohort with 1 year of follow up to demine incidence of cryptococcal meningitis and mortality7
Mamuye et al[20], 2016People living with HIV admitted at Tikur AnbessaTikur Anbessa (Black Lion) Hospital in Addis Ababa, a tertiary hospitalCrAg screening for those with CD4 ≤ 100 cells/mm3All CrAg positive patients underwent LPCross-sectional study to determine prevalve of CrAg8
Pac et al[35], 2015Adults PLHIV with CD4 < 250 cells/mm3, but we reported those with CD < 200 cells/mm3Kiboga District Hospital HIV clinic, a rural government hospitalCrAg screening for those with CD4 ≤ 200 cells/mm3. Routine provider-initiated screeningRefusalsProspective cohort to ascertain new cases of meningitis and mortality8
Nalintya et al[45], 2018Adults living with HIV with CD4 < 9 cells/mm311 HIV clinics in KampalaCrAg screening for those with CD4 ≤ 200 cells/mm3RefusalsProspective cohort study of HIV-infected patients to determine mortality9
Oyella et al[36], 2012Adults living with HIV with CD4 < 9 cells/mm3, no prior history of cryptococcal disease, not receiving fluconazole, both inpatients and outpatientsMulago Hospital, a tertiary hospital in UgandaCrAg screening for those with CD4 ≤ 9 cells/mm3Refusal, comatoseCross-sectional study to determine prevalence of CrAg antigenemia9
Ssebambulidde et al[46], 2019HIV-infected adults who presented with suspected meningitis and consented for LPMulago National Referral Hospital and Mbarara Regional Referral Hospital in UgandaCrAg screening for those with CD4 ≤ 200 cells/mm3All CrAg positive patients underwent LPProspectively consented HIV-infected adults who presented with suspected meningitis to evaluate for the etiology of meningitis9
Zono et al[47], 2024Asymptomatic outpatients with AHD (CD4 < 200 cells/mm3Multiple sites in Kinshasa, Democratic republic of CongoCrAg screening for those with CD4 ≤ 200 cells/mm3UndocumentedCross-sectional study to ascertain prevalence of CrAg and subtypes of Cryptococcal neoformans9
Eigege et al[48], 2024PLHIV aged ≥ 10 years newly diagnosed and presenting with a CD4+ cell count < 200 cells/mm328 health care facilities in NigeriaCrAg screening for those with CD4 < 200 cells/mm3Refusals (30%), lack of LP kits (27%), inability of patients to pay for LP (23%), pre-LP mortality (10%), lack of care worker competence (7%), and loss to follow-upProgrammatic evaluation of the implementation of AHD package of care8
Smitson et al[21], 2024ART experienced, CD4 < 200 cells/mm3Two ART clinics in Addis AbabaCrAg screening for those with CD4 ≤ 200 cells/mm3UndocumentedA retrospective study with 12-month of follow up to assess CrAg, mortality, loss to follow up9
Eric et al[49], 2023People with AHD (CD4 < 200 cells/mm3 or WHO stage III/IV)Mbale regional referral hospital and its associated clinics in UgandaCrAg screening for those with CD4 ≤ 200 cells/mm3 or WHO stage III/IV)All CrAg positive patients underwent LPCross-sectional study to determine prevalence of CrAg9
Beyene Tufa et al[50], 2017Adults living with HIV, CD4 < 150 cells/mm3Adama and Asella hospitals in EthiopiaCrAg screening for those with CD4 ≤ 200 cells/mm3All CrAg positive patients underwent LPCase-control study comparing the 6-month survival outcomes among CrAg positive and negative patients8
Wajanga et al[37], 2011Inpatients adults living with HIV, no history of CM, CD4 < 200 cells/mm3Bugando Medical Center, a tertiary hospitalCrAg screening for those with CD4 ≤ 200 cells/mm3All CrAg positive patients underwent LPProspective cohort to determine prevalence of CrAg9
Magambo et al[51], 2018Outpatients adults living with HIV, no history of CM, CD4 < 200 cells/mm3Bugando Medical Center, a tertiary hospital and Sekoture Regional HospitalCrAg screening for those with CD4 ≤ 200 cells/mm3All CrAg positive patients underwent LPCross-sectional study to determine prevalence of CrAg8
Wake et al[52], 201816 years or older, PLHIV with CD4 ≤ 9 cells/mm317 primary care clinics and 5 hospitals in South AfricaCrAg screening for those with CD4 ≤ 200 cells/mm3. Laboratory reflex screeningUndocumentedCross-sectional study to establish the prevalence of concurrent CM, and the relationship with blood CrAg titer8
Wake et al[53], 2020Adults (18 years or older) PLHIV with CD4 ≤ 9 cells/mm3Helen Joseph and Tambo Memorial Hospitals in South AfricaCrAg screening for those with CD4 ≤ 200 cells/mm3. Laboratory reflex screeningNot applicableProspective cohort study to investigate causes of morbidity and mortality during 6 months of follow-up among CrAg-positive and CrAg-negative8
Makadzange et al[19], 2021
Adults (18 years or older) PLHIV with CD4 ≤ 9 cells/mm3, both ART naïve and ART experienced20 outpatient facilities in Harare, ZimbabweCrAg screening for those with CD4 ≤ 9 cells/mm3RefusalsProspective cohort study to investigate mortality among CrAg-positive and CrAg-negative9
Blanco-Arévalo et al[54], 2019ART-naïve or poorly ART-adherent PLHIV (CD4 counts < 200 cells/mm3 or WHO stage III/IV)Manhiça district, MozambiqueNo country policy but the study adopted WHO guideline to screen for CrAg among those with CD4 ≤ 9 cells/mm3UndocumentedProspective cohort study to investigate CrAg and mortality8
Lakoh et al[38], 2020Patients aged 18 years or older with a CD4. Less than 9 cells/mm3 both inpatients and outpatientsConnaught tertiary adult referral hospital in Freetown, Siera LeoneNo country policy but the study adopted WHO guideline to screen for CrAg among those with CD4 ≤ 9 cells/mm3All CrAg positive patients underwent LPProspective cohort study to investigate CrAg and mortality8